Eluxadoline is a good choice for the treatment of irritable bowel syndrome (IBS) accompanied by diarrhea, according to the National Institute for Health and Care Excellence (NICE). That recommendation also assumes that the patient being considered for the drug has either not responded to other medications or cannot take them.

• NICE recommends eluxadoline for diarrhea-associated IBS if patients cannot tolerate or do not improve on first-line pharmacological agents, including antimotility agents, antispasmodics, and tricyclic antidepressants.
• The agency also recommends eluxadoline only be started in secondary care.
• The guideline specifically states that eluxadoline be discontinued after 4 weeks if it does not relieve symptoms.